

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**INSIDE INFORMATION – MARKETING AUTHORIZATION FOR
BIMATOPROST EYE DROP (晶貝清®) OBTAINED FROM THE
NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The Board is pleased to announce that the marketing authorization for Bimatoprost eye drop (晶貝清®), a drug researched, developed and manufactured by the Company for the treatment of glaucoma, has been obtained from the National Medical Products Administration (“**NMPA**”).

Bimatoprost eye drop (晶貝清®) is the first preservative-free single-dose bimatoprost eye drop in China. It is used to lower the intraocular pressure (“**IOP**”) in patients with open-angle glaucoma and ocular hypertension. Without preservatives, this drug avoids damage to the ocular surface caused by long-term use of preservative-containing drugs in glaucoma patients. At the same time, it helps to improve patient comfort during treatment and reduce the risk of preservative-related allergies. Daily medication frequency also helps to improve patient treatment compliance.

ABOUT BIMATOPROST

Bimatoprost is a PGA monotherapy eye drop that is used to treat open-angle glaucoma and ocular hypertension. According to China Insights Consultancy (CIC), bimatoprost is one of the most frequently prescribed PGAs for open-angle glaucoma in China. Bimatoprost eye drop (晶貝清®) developed by Zhaoke Ophthalmology is a generic to Lumigan, which was developed by Allergan. It is the first preservative-free single-dose bimatoprost eye drop in China.

ABOUT GLAUCOMA

According to CIC, glaucoma, the second-leading cause of blindness worldwide, is a chronic and progressive disease associated with high IOP, resulting in optic nerve damage. IOP is determined by the balance of the rate of fluid production versus fluid drainage in the eye. Generally speaking, all glaucoma cases are primary glaucoma and can be classified into two types, namely open-angle glaucoma and angle-closure glaucoma. In China, approximately 40% of the primary glaucoma cases are open-angle glaucoma.

China has the world's largest number of glaucoma patients, accounting for approximately a quarter of all glaucoma patients worldwide. It is estimated that the number of glaucoma patients in China was 21.8 million in 2020 and 5.67 million patients will go blind. In addition, the diagnosis rate of glaucoma is expected to increase significantly from 20.0% in 2019 to 60.6% in 2030.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman and executive Director

Hong Kong, September 19, 2024

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors, Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors, and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.